Breast Cancer Therapeutics in Asia-Pacific Markets Novel HER-2 Positive Therapies Provide Diversified Treatment Options to 2020

“The Report Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Novel HER-2 Positive Therapies Provide Diversified Treatment Options provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Novel HER-2 Positive Therapies Provide Diversified Treatment Options’, which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

View Report At :http://www.marketresearchreports.biz/analysis/196711

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.

The report includes:

  • Disease overview, as well as treatment algorithms and treatment usage patterns

  • Market size and forecast for the APAC breast cancer market from 2013 to 2020

  • Major marketed products in the APAC region along with a heat map of product performance

  • In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis

  • Key drivers and restraints that have had and are expected to have a significant impact upon the market

  • Key licensing and co-development agreements that could have impact on growth trends

Download Sample copy of this Report at : http://www.marketresearchreports.biz/sample/sample/196711

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

  • Align your product portfolio to the markets with high growth potential

  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth

  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market

  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies

  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

Table of Contents

1 Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 -Introduction 9

2.1 Breast Cancer 9

2.2 Symptoms 9

2.3 Epidemiology 10

2.4 Pathophysiology 11

2.5 Diagnosis 11

2.6 Prognosis and Disease Staging 12

2.6.1 Classification 13

2.7 Treatment Options 14

2.7.1 Surgery and Radiation Therapy 14

2.7.2 Chemotherapy 14

2.7.3 Hormonal Therapies 15

2.7.4 Targeted Therapies 15

2.7.5 Resistance to Pharmacological Therapies 16

2.7.6 Treatment Guidelines 16

2.7.7 Measuring the Effectiveness of Treatment 18

3 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products 20

3.1 Key Marketed Products 20

3.1.1 Herceptin 20

3.1.2 Halaven 22

3.1.3 Avastin 22

3.1.4 Gemzar 23

3.1.5 Taxotere 24

3.1.6 Tykerb 25

3.1.7 Femara 26

3.1.8 Aromasin 26

3.1.9 Zoladex 26

3.1.10 Arimidex 27

3.2 Heat Map for Marketed Products 27

4 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Pipeline Analysis 29

4.1 Overall Pipeline 29

4.2 Pipeline Analysis by Molecule Type 31

4.3 Pipeline Analysis by Mechanism of Action 33

4.4 Clinical Trials – Failure Rate 35

4.5 Clinical Trial Size 36

4.6 Duration 38

4.7 Promising Drug Candidates in Pipeline 39

4.7.1 Buparlisib 39

4.7.2 Palbociclib 39

4.7.3 Afatinib dimaleate 39

4.7.4 Entinostat 40

4.7.5 Neratinib 40

4.7.6 BMN-673 41

4.7.7 Etirinotecan pegol 41

5 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Market Forecast to 2020 42

5.1 Asia-Pacific Market 42

5.1.1 Treatment Usage Patterns 42

5.1.2 Market Size 42

5.2 India 44

5.2.1 Treatment Usage Patterns 44

5.2.2 Annual Cost of Therapy 44

5.2.3 Market Size 44

5.3 Australia 46

5.3.1 Treatment Usage Patterns 46

5.3.2 Annual Cost of Therapy 46

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Leave a Reply

banner